PUMA BIOTECHNOLOGY, INC.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.1M | $43.8M | $72.2M | $56.1M | $54.6M | $52.8M | $65.7M | $57.1M |
| Cost of Revenue | $10.7M | $10.7M | $24.3M | $13.3M | $11.9M | $13.2M | $16.8M | $12.5M |
| Gross Profit | $36.4M | $33.0M | $47.9M | $42.8M | $42.7M | $39.6M | $48.8M | $44.6M |
| Gross Margin | 77.4% | 75.5% | 66.3% | 76.3% | 78.3% | 75.0% | 74.4% | 78.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $25.0M | $21.8M | $20.2M | $22.8M | $24.5M | $22.5M | $25.0M | $24.0M |
| Operating Income | $-2.2M | $-2.3M | $14.8M | $8.6M | $4.9M | $4.4M | $10.0M | $2.4M |
| Operating Margin | -4.6% | -5.3% | 20.5% | 15.3% | 9.0% | 8.3% | 15.3% | 4.2% |
| Interest Expense | — | $3.4M | $3.4M | $3.3M | $3.3M | $3.3M | $3.3M | $2.9M |
| Pretax Income | $-4.2M | $-4.6M | $12.8M | $6.0M | $2.3M | $1.5M | $-5.3M | $-293.0K |
| Income Tax Expense | $378.0K | $220.0K | $536.0K | $213.0K | $187.0K | $147.0K | $294.0K | $67.0K |
| Net Income | $-4.5M | $-4.8M | $12.3M | $5.8M | $2.1M | $1.4M | $-5.6M | $-360.0K |
| Net Margin | -9.6% | -11.0% | 17.0% | 10.3% | 3.9% | 2.7% | -8.5% | -0.6% |
| EPS (Basic) | $-0.09 | $-0.10 | $0.26 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 |
| EPS (Diluted) | $-0.09 | $-0.10 | $0.25 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 |
| Shares Outstanding (Basic) | 48.3M | 48.2M | 47.1M | 47.5M | 46.8M | 46.6M | 44.7M | 45.6M |
| Shares Outstanding (Diluted) | 48.3M | 48.2M | 47.6M | 47.8M | 47.2M | 47.2M | 44.9M | 45.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |